Literature DB >> 5129311

Plasma insulin disturbances in primary hyperparathyroidism.

H Kim, R K Kalkhoff, N V Costrini, J M Cerletty, M Jacobson.   

Abstract

Plasma insulin dynamics were evaluated in 10 patients with primary hyperparathyroidism before and after parathyroidectomy and correction of hypercalcemia. Before surgery fasting plasma insulin concentrations and insulin responses to administered glucose, tolbutamide, and glucagon were significantly greater than postoperative values. Hyperinsulinemia was not associated with altered glucose curves during glucose or glucagon tolerance tests, but a relatively greater insulin response to tolbutamide resulted in an increased hypoglycemic effect following its administration. The glucose-lowering action of intravenous insulin was slightly impaired before treatment. Intramuscular injections of parathormone to six normal men for 8 days induced mild hypercalcemia and hypophosphatemia and reproduced augmented plasma insulin responses to oral glucose and intravenous tolbutamide. 4-hr intravenous infusions of calcium to another group of six normal men raised serum calcium concentrations above 11 mg/100 ml. This did not alter glucose or insulin curves during oral glucose tolerance but markedly accentuated insulin responses to tolbutamide and potentiated its hypoglycemic effect. When highly purified parathormone was incubated with isolated pancreatic islets of male rats, glucose-stimulated insulin secretion was unaffected. These findings suggest that chronic hypercalcemia of hyperparathyroidism sustains a form of endogenous insulin resistance that necessitates augmented insulin secretion to maintain plasma glucose homeostasis. This state is insufficient to oppose tolbutamide-induced hypoglycemia because of an additional direct, selective enhancement of hypercalcemia on pancreatic beta cell responsiveness to the sulfonylurea. The possible direct role of parathormone in these events has not been established.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5129311      PMCID: PMC292209          DOI: 10.1172/JCI106760

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  37 in total

Review 1.  Effects of Ca ions on membranes.

Authors:  J F Manery
Journal:  Fed Proc       Date:  1966 Nov-Dec

2.  Alpha cell hyperplasia in calcific pancreatitis associated with hyperparathyroidism.

Authors:  E Paloyan; A M Lawrence; F H Straus; D Paloyan; P V Harper; D Cummings
Journal:  JAMA       Date:  1967-05-29       Impact factor: 56.272

Review 3.  The growth-promoting and anti-insulin actions of somatotropin.

Authors:  W H Daughaday; D M Kipnis
Journal:  Recent Prog Horm Res       Date:  1966

4.  Method for the isolation of intact islets of Langerhans from the rat pancreas.

Authors:  P E Lacy; M Kostianovsky
Journal:  Diabetes       Date:  1967-01       Impact factor: 9.461

5.  Regulation of insulin secretion studied with pieces of rabbit pancreas incubated in vitro.

Authors:  H G Coore; P J Randle
Journal:  Biochem J       Date:  1964-10       Impact factor: 3.857

6.  Role of Na+ and K+ on sugar (2-deoxyglucose) and amino acid (alpha-aminoisobutyric acid) transport in striated muscle.

Authors:  D M Kipnis; J E Parrish
Journal:  Fed Proc       Date:  1965 Sep-Oct

7.  Na+ -dependent transport in the intestine and other animal tissues.

Authors:  R K Crane
Journal:  Fed Proc       Date:  1965 Sep-Oct

8.  Effects of diazoxide on insulin secretion in vitro.

Authors:  S L Howell; K W Taylor
Journal:  Lancet       Date:  1966-01-15       Impact factor: 79.321

9.  Effect of glucocorticoids on plasma insulin.

Authors:  M Perley; D M Kipnis
Journal:  N Engl J Med       Date:  1966-06-02       Impact factor: 91.245

10.  The mode of inhibition by calcium of cell-membrane adenosine-triphosphatase activity.

Authors:  F H Epstein; R Whittam
Journal:  Biochem J       Date:  1966-04       Impact factor: 3.857

View more
  19 in total

1.  Diabetes mellitus and primary hyperparathyroidism.

Authors:  C H Walsh; N G Soler; J M Malins
Journal:  Postgrad Med J       Date:  1975-07       Impact factor: 2.401

Review 2.  The role of Klotho in energy metabolism.

Authors:  M Shawkat Razzaque
Journal:  Nat Rev Endocrinol       Date:  2012-05-29       Impact factor: 43.330

3.  Evaluation of glucose tolerance, insulin secretion, and insulin action in patients with primary hyperparathyroidism before and after surgery.

Authors:  R Prager; G Schernthaner; B Niederle; R Roka
Journal:  Calcif Tissue Int       Date:  1990-01       Impact factor: 4.333

Review 4.  The pathophysiology and clinical aspects of hypercalcemic disorders.

Authors:  D B Lee; E T Zawada; C R Kleeman
Journal:  West J Med       Date:  1978-10

5.  Role of calcium and cyclic adenosine 3',5'-monophosphate in the antilipolytic effect of tolbutamide and glibenclamide.

Authors:  R Ebert; O Hillebrandt; U Schwabe
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

6.  Potentiation of glibenclamide-induced insulin release by calcium infusion.

Authors:  L Gero; E Baranyi; K Steczek; G Petrányi; G Tamás
Journal:  Diabetologia       Date:  1977-08       Impact factor: 10.122

7.  Target cells for 1,25 dihydroxyvitamin D3 in the pancreas.

Authors:  S A Clark; W E Stumpf; M Sar; H F DeLuca; Y Tanaka
Journal:  Cell Tissue Res       Date:  1980       Impact factor: 5.249

8.  Endocrine abnormalities in primary hyperparathyroidism.

Authors:  D V Hamilton; J S Pryor
Journal:  Postgrad Med J       Date:  1981-03       Impact factor: 2.401

9.  Primary hyperparathyroidism is associated with decreased insulin receptor binding and glucose intolerance.

Authors:  R Prager; G Schernthaner; J Kovarik; G Cichini; K Klaushofer; R Willvonseder
Journal:  Calcif Tissue Int       Date:  1984-05       Impact factor: 4.333

10.  Carbohydrate metabolism and uraemia-mechanisms for glycogenolysis and gluconeogenesis.

Authors:  W H Hörl; J Stepinski; A Heidland
Journal:  Klin Wochenschr       Date:  1980-10-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.